McKesson is set to acquire Precision Medicine Group for roughly $2.25 billion, according to reports from Seeking Alpha and Quartz. The transaction is described as a move by the drug distributor to expand into clinical research and biopharma commercialization activities.
Both outlets characterize the deal as focused on Precision Medicine Group’s role in supporting oncology-related drug development and commercialization. Quartz adds that, once the acquisition closes, McKesson will fold Precision Medicine Group into its oncology unit. The reports frame the purchase as a strategic bet on clinical research capabilities, though they do not provide extensive detail in the excerpts beyond the price and intended integration.
Overall, the outlets align on the deal size and the acquisition’s general purpose, while Quartz provides more specific information on how the acquired company will be integrated into McKesson’s oncology operations after closing.
